Jazz Pharmaceuticals on the acquisition of Cavion, Inc. a company that creates therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.
Medigene AG in US$1bn+ deal with bluebird bio to establish a strategic T cell receptor alliance in cancer immunotherapy.
Gilead Sciences on the technology license agreement with Xencor, Inc., a company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma, and allergic diseases.
Novartis on its US$665m acquisition of Selexys Pharmaceuticals and with its landmark portfolio transformation transactions with GSK and Eli Lilly.
A leading Japanese innovator pharmaceutical firm in numerous Hatch-Waxman actions in relation to generic versions of its product.
DepoMed in patent suit and IPRs against Endo Pharmaceuticals relating to Opana® ER; PTAB upheld Depomed's patents on controlled release gastric retentive technology.
Merck Sharp & Dohme in Hatch-Waxman actions against Hospira and Sandoz in relation to Merck’s antibiotic drug, Invanz®.
Serving as national product liability counsel for Bristol-Myers Squibb in a mass tort involving allegations that Abilify causes compulsion gambling.
A global pharmaceutical company on multijurisdictional personal injury litigation and coordinating the client's defense in more than 27 countries.
A biotechnology manufacturer in investigation of multiple whistleblower allegations that the company promoted a surgical implant for off-label use.
Conducted internal investigations at global pharmaceutical companies into allegations of money laundering, international corruption, and fraudulent practices related to asset transfers in multiple countries.
Band 1 for Life Sciences
Chambers Global: Multi-Jurisdictional
Life Sciences Europe-wide
Chambers Europe
Band 1 for Life Sciences in Japan
Chambers Asia-Pacific
